‘Unresolvable conflict’: are links to big tobacco changing inhaler prescribing?
The takeover of inhaler company Vectura by tobacco firm Philip Morris International has stirred up debate and controversy, with experts raising questions around whether the NHS is doing enough to make the connection clear to prescribers and patients.
When Marlboro cigarette maker Philip Morris International (PMI) took over UK-based asthma inhaler company Vectura in September 2021, there was immediate backlash.
Get unlimited access to all content
You’ve reached your limit of premium articles on The Pharmaceutical Journal for this month.
